NEW YEAR IN THE CAPITAL DISTRIBUTED WITH
16TH JANUARY 2023
Health , fitness & beauty
13
Ditch foggy glasses and dry contacts….
Get the visual freedom you deserve! Te EVO ICL lens (EVO) allows you to unlock visual freedom and help you see the world the way it’s meant to be seen — with sharp, clear vision1
Myopia (or short-sightedness) is
the most common vision disorder worldwide and its prevalence is increasing rapidly. An estimated 30% of the world’s population, or 2.6 billion people, have myopia and this number is projected to rise to 50% of the global population by the year 2050.2 For some people, contact lenses and eyeglasses can be inhib- iting, especially for those who seek visual freedom. EVO ICL* really is an evolution in visual freedom — a clinical- ly-proven implantable lens that works in harmony with your natural eye to correct short-sightedness, with or without astigmatism. EVO ICL is designed for people who are seeking visual
freedom from
their glasses or contact lenses and are looking for a different solution to laser-based vision correction procedures. Te EVO procedure is different from other vision correction options, like LASIK, performed by ophthal- mologists. Te EVO lens is additive, meaning it’s added to the eye and doesn’t remove corneal tissue or the natural crystalline lens. Te EVO ICL lens can correct vision on a long-term basis and, if desired, is removable by a surgeon for added peace of mind, giving you flexibility for the future, while helping to elim- inate dependency on glasses and contact lenses now. Te
EVO procedure involves
implanting a biocompatible, flexible EVO lens made from Collamer® into the eye between the iris (coloured part of the eye) and the natural lens
to correct vision. Te EVO procedure
is
a
20-30
minute outpatient procedure per eye with a quick recovery and little downtime typically. Many patients notice an improvement in vision immediately after the procedure. It doesn’t require the removal of corneal tissue; thus, it may even be suitable for patients with thin corneas.3 Te EVO lens works in harmony with the natural eye while deliv- ering sharp, clear vision, excellent night vision, UV protection, and does not cause dry eye syndrome. 1,3,4 According to a STAAR Surgical patient
survey, 99.4% of patients
would elect to have the EVO ICL procedure again.5 Te EVO ICL lens is an option for patients who are seeking to break free from glasses or contact lenses, aged between 21-60 years of age, who are short-sighted with mild to severe myopia (-0.5 D to -20 D), with or without astigmatism between 0.5 and 6.0 D.
Day or night, you can rely on EVO for exceptional vision 1,3 Te EVO ICL lens is approved and marketed throughout Europe, Asia, North America, and the rest of the world. In fact, over 2,000,000 EVO ICL lenses have been distributed around the world. Te EVO ICL lens is available throughout the United Kingdom through ophthalmologists certified by STAAR Surgical.
EVO ICL Benefits Include: • Sharp, clear vision1 • Works in harmony with natural eye • Removable by your surgeon • No removal of cornea tissue • Excellent night vision1,3 • UV protection • Does not cause dry eye syndrome4 • Suitable for thin corneas6
and high prescriptions
• Quick procedure; little down time • Proven, time-tested procedure for more than a decade
To find an EVO ICL provider near you, please scan the QR
code. For more information, visit:
uk.discovericl.com
* EVO ICL FAMILY OF LENSES INCLUDE EVO ICL, EVO+ ICL, EVO TORIC ICL, EVO+ TORIC ICL IMPORTANT SAFETY INFORMATION IMPLANTATION OF THE EVO/EVO+ ICL IS A SURGICAL PROCEDURE, AND AS SUCH, CARRIES POTENTIALLY SERIOUS RISKS. THE EVO/EVO+ ICL IS DESIGNED FOR THE CORRECTION/REDUCTION OF UP TO -20 DIOPTRES (D) OF SHORT-SIGHTEDNESS WITH UP TO 6 D OF ASTIGMATISM FOR PATIENTS WHO ARE 21 TO 60 YEARS OF AGE. BEFORE CONSIDERING EVO/EVO+ ICL SURGERY YOU SHOULD HAVE A COMPLETE EYE EXAMINATION AND TALK WITH YOUR EYE CARE PROFESSIONAL ABOUT THE PROCEDURE, ESPECIALLY THE POTENTIAL BENEFITS, RISKS AND COMPLICATIONS. YOU SHOULD DISCUSS THE TIME NEEDED FOR HEALING AFTER SURGERY. FOR ADDITIONAL INFORMATION WITH POTENTIAL BENEFITS, RISKS AND COMPLICATIONS PLEASE VISIT
DISCOVERICL.COM. FOR ADDITIONAL IMPORTANT SAFETY INFORMATION, PLEASE VISIT
UK.DISCOVERICL.COM
REFERENCES: 1. MARTINEZ-PLAZA E, LOPEZ-MIGUEL A, LOPEZ-DE LA ROSA A, ET AL. EFFECT OF THE EVO+ VISIAN PHAKIC IMPLANTABLE COLLAMER LENS ON VISUAL PERFORMANCE AND QUALITY OF VISION AND LIFE, AM J OPHTHALMOL 2021;226: 117–125. 2. HOLDEN B, FRICK T, WILSON D ET AL. GLOBAL PREVALENCE OF MYOPIA AND HIGH MYOPIA AND TEMPORAL TRENDS FROM 2000 THROUGH 2050 (OPHTHALMOLOGY 2016;123:1036-1042). 3. PARKHURST GD. A PROSPECTIVE COMPARISON OF PHAKIC COLLAMER LENSES AND WAVEFRONT-OPTIMIZED LASER-ASSISTED IN SITU KERATOMILEUSIS FOR CORRECTION OF MYOPIA. CLIN OPHTHALMOL. 2016 JUN 29;10:1209-15. 4. GANESH S, BRAR S, PAWAR A. MATCHED POPULATION COMPARISON OF VISUAL OUTCOMES AND PATIENT SATISFACTION BETWEEN 3 MODALITIES FOR THE CORRECTION OF LOW TO MODERATE MYOPIC ASTIGMATISM. CLIN OPHTHALMOL. (AUCKLAND, NZ). 2017;11:1253-63 5. PACKER M. THE IMPLANTABLE COLLAMER LENS WITH A CENTRAL PORT: REVIEW OF THE LITERATURE. CLINICAL OPHTHALMOLOGY 2018: 12: 2427–2438. 6. PARKHURST GD, PSOLKA M, KEZIRIAN GM. PHAKIC INTRAOCULAR LENS IMPLANTATION IN UNITED STATES MILITARY WARFIGHTERS: A RETROSPECTIVE ANALYSIS OF EARLY CLINICAL OUTCOMES OF THE VISIAN ICL. JOURNAL OF REFRACTIVE SURGERY (THOROFARE, NJ : 1995). 2011;27(7):473-81
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32